Phase 2 N=106 S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression-free Survival — 2.0; 4.3 months — p=0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=250 Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
Diabetes Mellitus, Type 2
Primary: Mean Change From Baseline in Hemoglobin A1c (Glycosylated Hemoglobin) (HbA1c) at Week 12 — -0.19; -0.53; -0.75; -0.53 Percentage — p=0.003
Phase 2 N=40 Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity
Obesity
Primary: Gastric Emptying of Solids Half-time (T1/2) at 5 Weeks — 180; 117 minutes
Phase 2 N=9 Vitamin D to Improve Endothelial Function in SLE
Atherosclerosis · Systemic Lupus Erythematosus
Primary: Change at Week 16 in % Flow Mediated Dilation in Those Who Did and Did Not Replete Vitamin D — 1.4; -4.2 Absolute change in % FMD — p=> 0.05
Phase 2 N=526 A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
Acute Coronary Syndrome
Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 97; 138; 131; 269 Participants
Phase 2 N=407 Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older
Influenza
Primary: Demonstrate That the Immunogenicity of Adjuvanted Panblok H7 rHA is Sufficient to Support Emergency Use Authorization in the Event of a Declared Pandemic. — 11; 9; 15; 1…
Phase 2 N=1 Pioglitazone in Thyroid Cancers
Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
Primary: Tumor Response (Change) — 6.0; 3.9 cm
Phase 2 N=81 Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Lung Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Safety and Toxicity of Erlotinib Hydrochloride and Docetaxel as Measured by NCI CTC v3.0 on Day 8 of Course 1 and on Day 1 of Every Subsequent Course (Phase I [Completed…
Phase 2 N=306 Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Percentage of Subjects With Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response at Week 24 Using Screening Visit as Baseline — 57.8; 53.8; 44.0 percentage…
Phase 2 N=10 A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
Adenocarcinoma of the Endometrium
Primary: IHC-based Tissue Markers of Proliferation
Phase 2 N=214 Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Primary: Progression-free Survival (PFS) — 111; 169; 183 days
Phase 2 N=181 A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
Alzheimer's Disease Psychosis
Primary: Antipsychotic Efficacy — -1.93; -3.76 Score on the NPI-NH scale — p=0.0451
Phase 2 N=86 Mirtazapine for Treating Cocaine Dependent Individuals Who Also Suffer From Depression
Cocaine Dependence · Depression
Primary: Cocaine Abstinence During Last Three Weeks of Study — 5; 9 participants
Phase 2 N=48 Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients
Food Allergy
Primary: Desensitization Measured by Proportion of Food Allergic (FA) Participants Who Pass a DBPCFC to 2,000 mg Protein for Each of 2 Allergens at Week 36 — 30; 4 Participants
Phase 2 N=21 Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients
Disorder Related to Lung Transplantation · Bronchiolitis Obliterans · Decreased Immunologic Activity
Primary: Number Of Participants With Chronic Rejection Who Met Primary Combined End-point — 2; 5 Participants — p=0.03